ABSTRACT -Thirty-two children (21 female and 11 male), between 7 and 14 years old, with chronic daily headache (CDH) were consecutively included in a prospective, randomized, double blind, placebo cont rolled crossover study. The patients were divided in group I (fluoxetine vs. placebo), with 17 patients and g roup II (placebo vs. fluoxetine), with 15 patients. After one month of baseline headache frequency re c o rding, the patients received fluoxetine in dosages from 0.25 to 0.50 mg/kg for three months. A wash out period of one month was followed by another three months treatment period. Results showed a significant decrease in headache frequency in the study period [78% reduction in group I (p<0.025), and 45% reduction in group II (p=0.025)]. Gastrointestinal adverse effects were observed in nine patients (29%) that received fluoxetine, compared with 3 (10%), with placebo. We conclude that fluoxetine efficacy is not higher than placebo in the prophylaxis of CDH in children and adolescents.
The term chronic daily headache (CDH) is used to refer to headaches that occur 15 days/month. Silberstein et al. 1 classified CDH into two types, each with or without medication overuse. CDH is divided into primary and secondary varieties. Prim a ry CDH can be subclassified into disorders of s h o rt(<4 hours) and long (>4 hours) duration. Primary CDH of long duration include chronic tension-type headache, chronic migraine (pre v i o u s l y called transformed migraine), new daily persistent headache and hemicrania continua 1 . In adults, 4-5% of the general population have CDH 2 . There a re few studies addressing CDH in children. Almost 50% of children with frequent headaches are left without diagnosis, when the adult diagnostic criteria are used in this age group, what lead to the p roposal of a new CDH category for children called comorbid or mixed pattern, that includes cases in which migrainous and tension-type headache patt e rns exist independently of each other, without any transform a t i o n 3 , 4 . Abu-Arafeh 5 studied 115 c h i l d ren and adolescents with almost daily headache and found that 63.5% had chronic tensiontype headaches, while 30.4% had independent episodes of migrainous and tension-type headaches, the comorbid type, and only 4.3% were classified as analgesic overuse headache. Among 40 c h i l d ren and adolescents with chronic daily headaches over the last 6 months, we found 65% of t r a n s f o rmed migraine, 17.5% of the mixed patt e rn and 17.5% of chronic tension-type headache 6 . The treatment of primary CDH is complicated by analgesic overuse, comorbid psychiatric disord e r s , low frustration tolerance and emotional pro b l e m s in adults. There are few well-designed studies in the literature, although the antidepressant amitriptyline and several drugs used for migraine pro p h ylaxis seem to be useful 2 . Fluoxetine, a selective sero t o n i n -reuptake inhibitor antidepressant, is a phenylpro p y l a m i n e -d e r i vative. The drug differs structurally from other selective sero t o n i n -reup take inhibitor antidepre s s a n t s (e.g., citalopram, paroxetine, sertraline) and also d i ffers structurally and pharmacologically fro m other currently available antidepressant agents (e.g., tricyclic antidepressants, monoamine oxidase inhibitors). Fluoxetine is widely used as antidepre ssive in adults, as well as in children and adolescent s 7 . Efficacy of fluoxetine for migraine pro p h y l a xis was re p o rted by some authors 8 , 9 , while others w e re unable to observe such eff e c t 1 0 . A doubleblind placebo-controlled study showed fluoxetine to be useful in the treatment of chronic daily head a c h e 1 1 . Others, using it in association with amitriptyline, could not observe this effect 12 . The objective of this study was to test the eff icacy of fluoxetine prophylaxis in a group of child ren and adolescents with primary CDH thro u g h a prospective, randomized, double blind, placebo-controlled, crossover study.
METHOD
F rom January 1999 to April 2002, 40 children (30 female and 10 male), between 7 and 14 years old, with a diagnosis of primary CDH according to the Silberstein criteria were seen in the outpatient headache clinic. Thirty-two patients (21 female and 11 male) agreed to participate in our study. The ethics commission of our institution previously approved the study protocol and a signed informed consent was obtained from the pare n t s .
All patients had a normal neurological examination and were instructed to fill out questionnaires of selfevaluation for depression, anxiety and life quality.
None of the patients used common analgesics more than 10 days/month during the study period. Patients w e re allowed to take the analgesics that were curre n tly used before the beginning of the study. No patient used analgesics containing narcotics. The authors did not change the type of analgesic that was being used b e f o re the study period. Only the dosage was adjusted a c c o rding to the patient's age and weight. The most commonly used were paracetamol and dipirone, with or without caffeine, isomeptene, and ergotamine. Analgesics for acute pain relief were allowed during the wash-out period as well.
E n v i ronmental factors were not controlled during the study period, but no specific advices were given conc e rning daily activities, sleep or food habits, to the patients or their families.
All patients had a primary headache with a headache f requency of 15 days/month, for a period of at least 6 months before the initial evaluation. CDH diagnosis was based on Silberstein et al. 1 and Gladstein and Holden 3 modified criteria for children. Chronic daily migraine ( t r a n s f o rmed migraine) included meeting Intern a t i o n a l Headache Society (IHS) criteria for migraine in the past, daily or almost daily (>15 days/month) headache for more than 1 month, average headache duration of 4 hours, and a history of increased headache frequency with dec reased migraine symptoms over the last 3 months 1 . Criteria for chronic tension-type headache included headache frequency of more than 15 days per month, with a duration of pain lasting more than 4 hours per day for at least 6 months. Also, patients should have pressing, bilateral pain with mild to moderate severity that is not aggravated by physical activity. There should be a history of episodic tension-type headache in the past, with an evolution to daily headaches in the past 3 m o nths, and an absence of autonomic symptoms 1 . Mixed (or comorbid) pattern included patients with a high frequency of migraine headache symptomatology interm ixed with tension type headache 3 . The patients were randomly assigned to two gro u p s : group I received fluoxetine and later placebo, and gro u p II that started with placebo and received fluoxetine in the last study period. After one month of baseline headache frequency re c o rding, the patients received fluoxetine (or placebo) in dosages that varied from 0.25 to 0.50 mg/kg for three months. A wash out period of one month was followed by another three months period of drug treatment (Fig 1) .
The drug were delivered in solution flasks of 50 ml (10 mg/ml of fluoxetine) labeled with the letters A or B. The initial fluoxetine dosage was 0.25 mg/kg/day, adm i n i s t e red once a day, in the morning, and was eventually increased up to a maximum dosage of 0.5 mg/kg/ d a y, or 20 mg/day, according to the therapeutic re s p o n s e (reduction <50% of headache frequency).
Monthly visits were scheduled where headache frequency and adverse effects were re c o rded through a headache diary. The presence and intensity of adverse effects lead to dosage decrease, or drug withdrawal.
D rug compliance was monitored through the flasks residual volume, after each visit.
The following tests were used for statistical analysis: 1. Friedman test for rank variance analysis, with the objective of comparing headache fre q u e n c y, for each patient, in each visit, and, when significant, was complemented by the test of multiple comparisons. 2. Wi l c o x o n test comparing the baseline and final headache fre q u e ncy for each patient. Significance value was p<.05. The test power was established at 80%, for a decrease in headache frequency of 50%. RESULTS G roup I included 17 patients (11 female, 6 male) and group II, 15 patients (10 female, 5 male). Of the 17 patients initially included in group I, 7 completed the whole study, 4 completed only the first t h ree months period, and 6 abandoned the study for several reasons (2 for lack of response, 3, due to adverse effects, and one moved to another state). In group II, of the 15 initially randomized patients, 10 completed the study, 2 completed only the first three months period, and 3 dropped out (one due to adverse effects and 2 for ignored re asons).
Seventeen patients completed the whole study period, 7 in group I, and 10, in group II, and data on these patients were used for statistical analysis purposes. The sex distribution, mean age, initial and final headache fre q u e n c y, and CDH diagnosis are shown in the Table. Seventy percent of the patients were classified as chronic daily migraine (transformed migraine), 23.5%, as mixed (comorbid) pattern, and only one patient, as chro nic tension-type headache.
T h e re was no statistically significant diff e re n c e between the children that completed the study and the dropouts concerning age, sex, headache f re q u e n c y, analgesic intake, headache diagnosis, and questionnaires ranks of anxiety, depre s s i o n and life quality.
Six of the seventeen patients that completed the study (35.3%) had scores that suggested a dep ressive trait, two patients of group I, and 4, of g roup II. Four (23.5%) patients had scores that revealed a high anxiety status, one of group I, and 3, of group II. Four patients (23.5%) had low score s in the quality of life questionnaire, one of group I, and 3, of group II.
Headache frequency during the study period is shown in Fig 2. The mean monthly headache frequency of g roup I (fluoxetine) decreased from 18.8 to 5.7 (70% reduction), and of group II (placebo), fro m 23.9 to 14.2 (40% reduction), during the first thre e months period. Statistical analysis using Friedman variance test for ranks showed a significant decre ase in headache frequency in both group I (p<0.02) and group II (p<0.02) after the first three months period (Fig 3) . In the last three months period the mean monthly headache frequency decreased from 7.1 to 4.1 (42% reduction), in group I, while in group II, the f requency decreased from 18.7 to 13.1 (30% re d u ction), as shown in Fig 2. In the second study period, we only observed a significant decrease of the monthly headache frequency in patients re c e i v i n g placebo (p<0.001). There was no significant decre ase in headache frequency in patients taking fluoxetine (Fig 2) .
We observed that both groups had a significant decrease of headache frequency when we c o m p a red the initial baseline frequency with that re c o rded at the end of the seven months of the study period. Patients in group I had a decre a s e of mean monthly headache frequency from 18.8 to 4.1 (p<0.025), a 78% reduction, and patients in g roup II, from 23.9 to 13.1 (p=0.025), a 45% re d u ction, as shown in Fig 2. T h i rty-one patients received at least one month of fluoxetine and 29, of placebo. Nine patients (29%) re f e rred adverse effects possibly related to fluoxetine, and four had the drug withdrawn and could not complete the study. Three patients (10%) receiving placebo complained of adverse eff e c t s . Gastrointestinal system complaints (nausea, diarrhea) were the only adverse effects recorded.
DISCUSSION
Considering the whole study period (seven months), our study showed a statistically significant decrease in headache frequency that was independent of the drug. The reduction was statistically significant for patients taking either flu- oxetine, or placebo, in the first three months, and only for patients on placebo, in the last thre e months. The overall reduction, considering the 17 patients that completed the whole study period, was of 60% of the initial headache fre q u e n c y. These results indicate that CDH in children and adolescents has a natural history that is more benign, in terms of spontaneous decrease of headache frequency, from that observed in adults.
The placebo effect observed in our study was of 40% reduction in headache frequency in both p a rts of the study, a higher rate than that observ e d by others in adults, around 25-30% 10, 11 .
Although several patients exhibited psychological traits suggestive of depression and anxiety, we could not establish their role in headache fre q u e ncy variation due to the small sample size.
The low number of patients that completed the study could be a confounding factor in the interp retation of the results. A high drop out rate with studies using this methodology and the long tre a tment period is a problem frequently observed. We a g ree that a higher number of patients would be desirable. Notwithstanding, when perf o rming studies looking for higher than 40% effectiveness in s y m p t o m 's reduction, together with long study periods, the number of patients needed for valid statistical purposes is considerably reduced, and our data is within the values re q u i re d 1 3 . We tried to design the study according to recent re c o m m e ndation of the IHS for the study of drug efficacy in headache patients 1 4 , and we could not find any other study in the literature that used this strict methodology in children and adolescents.
We conclude that fluoxetine is not superior to placebo in the treatment of CDH in children and adolescents. CDH in this age group may have a diff e rent natural history from that observed in adults. The high rate of spontaneous reduction of headache frequency over several months observed in our study is a fact that should lead to other studies t h a t a d d ress the basic mechanisms for CDH maintenance in children. This should be taken into account when studying CDH in this age group.
